Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma

Trial Profile

Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs CV 8102 (Primary)
  • Indications Adenoid cystic carcinoma; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors CureVac
  • Most Recent Events

    • 07 Nov 2018 According to a CureVac's media release, preliminary data will be presented at the 2018 Society of Immunotherapy of Cancers (SITC) 33rd Annual Meeting.
    • 28 Aug 2018 Planned number of patients changed from 104 to 146.
    • 27 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top